文献速递肝病消化道肿瘤与早癌消化内镜

原发性硬化性胆管炎相关胆管癌的基因组特征揭示治疗机会

Genomic Characterization of Cholangiocarcinoma in Primary Sclerosing Cholangitis Reveals Therapeutic Opportunities.
PubMed 文献 · Hepatology · 2020-08-19

该研究分析了来自8国11个中心的186例原发性硬化性胆管炎相关胆管癌(PSC-BTC)患者的肿瘤组织,进行42个临床相关基因位点的DNA测序及组织形态学与免疫组化分析。结果显示PSC-BTC无论解剖部位如何,均呈现类似肝外胆管癌的均一分子与组织学特征,且包含较高频率的可靶向治疗变异。

要点

  • PSC-BTC呈现肝外胆管癌样均一分子表型,不依赖肿瘤解剖位置。
  • 常见基因变异包括TP53、KRAS、CDKN2A和SMAD4,并存在HER2/ERBB2等潜在可靶向突变。
  • 非典型/非导管组织学亚型及导管内乳头状瘤变 precursor 病变频率较高。

核心结论

  • PSC-BTC的基因组变异包含相当数量的推定可靶向治疗靶点,且呈现独立的肝外形态分子表型。

研究设计与样本

  • 分析来自8个国家11个中心的186例PSC-BTC患者FFPE肿瘤组织,涵盖所有解剖位置。
  • 对42个临床相关基因位点进行肿瘤DNA测序以检测突变、易位和拷贝数变异,并进行组织形态学与免疫组化表征。

主要发现

  • 无论解剖位置,PSC-BTC均表现类似肝外胆管癌的均一分子与组织学特征。
  • 检测到肝外胆管癌典型基因组变异高频出现:TP53(35.5%)、KRAS(28.0%)、CDKN2A(14.5%)、SMAD4(11.3%)。
  • 存在潜在可成药突变(如HER2/ERBB2)。
  • 非典型/非导管组织形态学亚型频率为55.2%,通常罕见的BTC前驱病变导管内乳头状瘤变频率为18.3%。

关键数值与推荐

  • TP53变异频率35.5%,KRAS 28.0%,CDKN2A 14.5%,SMAD4 11.3%(186例PSC-BTC肿瘤组织测序)。
  • 非典型/非导管组织形态学亚型占55.2%,导管内乳头状瘤变占18.3%。

临床怎么用

  • 对PSC-BTC患者可考虑基于基因组变异的个体化治疗策略,并鼓励开展相关临床试验。
  • 病理评估需关注非典型/非导管组织学亚型及导管内乳头状瘤变等前驱病变。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Lifetime risk of biliary tract cancer (BTC) in primary sclerosing cholangitis (PSC) may exceed 20%, and BTC is currently the leading cause of death in patients with PSC. To open new avenues for management, we aimed to delineate clinically relevant genomic and pathological features of a large panel of PSC-associated BTC (PSC-BTC). APPROACH AND RESULTS: We analyzed formalin-fixed, paraffin-embedded tumor tissue from 186 patients with PSC-BTC from 11 centers in eight countries with all anatomical locations included. We performed tumor DNA sequencing at 42 clinically relevant genetic loci to detect mutations, translocations, and copy number variations, along with histomorphological and immunohistochemical characterization. Regardless of the anatomical localization, PSC-BTC exhibited a uniform molecular and histological characteristic similar to extrahepatic cholangiocarcinoma. We detected a high frequency of genomic alterations typical of extrahepatic cholangiocarcinoma, such as TP53 (35.5%), KRAS (28.0%), CDKN2A (14.5%), and SMAD4 (11.3%), as well as potentially druggable mutations (e.g., HER2/ERBB2). We found a high frequency of nontypical/nonductal histomorphological subtypes (55.2%) and of the usually rare BTC precursor lesion, intraductal papillary neoplasia (18.3%). CONCLUSIONS: Genomic alterations in PSC-BTC include a significant number of putative actionable therapeutic targets. Notably, PSC-BTC shows a distinct extrahepatic morpho-molecular phenotype, independent of the anatomical location of the tumor. These findings advance our understanding of PSC-associated cholangiocarcinogenesis and provide strong incentives for clinical trials to test genome-based personalized treatment strategies in PSC-BTC.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Goeppert B, Folseraas T, Roessler S, et al. Genomic Characterization of Cholangiocarcinoma in Primary Sclerosing Cholangitis Reveals Therapeutic Opportunities. Hepatology. 2020. PMID: 31925805. doi:10.1002/hep.31110

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。